Revolution Medicines, Inc.

RVMD Healthcare Biotechnology

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022. In the quarter to June 2026, EPS fell 133.6%, free cash flow fell 70.0% and total debt rose 322.7%, each against the same quarter a year earlier.

177.96 11.30 −5.97%
Market cap
$40.6B
P/E
0.0×
Fwd P/E
−11.9×
Dividend yield
—
F-score
4/9
Altman Z
7.73
Beneish M
−4.29
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
8.05 7.14 6.80 11.38
Net Debt/EBITDA
5.29 4.86 3.67 5.75
Debt/Equity
0.16 0.16 0.19 0.40
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(1.11) (1.45) (1.80) (1.85)
Book value per Share
8.44 8.58 7.57 12.36
Free Cash Flow
(210.66) (276.16) (355.70) (389.60)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates